EU Funds €6.5M Multi-Site Psilocybin Study for Palliative Patients
The European Union has granted €6.5 million to fund a multi-site study, called PsyPal, to investigate the use of psilocybin therapy in addressing psychological and existential distress in patients with progressive illnesses such as multiple sclerosis, chronic obstructive pulmonary disorder, atypical Parkinsonism, and amyotrophic lateral sclerosis. The study, which is the first of its kind in Europe, aims to enroll 100 patients across four clinical sites and will explore the safety, efficacy, and cost-effectiveness of psilocybin therapy in non-oncology palliative care. The project involves a consortium of 19 European organizations and is expected to commence in 2025, with results anticipated in 2027.
